New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci

Reviews and Research in Medical Microbiology

Volumn 15, Issue 3, 2004, Pages 109-117

  Bassetti, Matteo ^a,b   Melica, Giovanna ^a   Di Biagio, Antonio ^a   Righi, Elda ^a   Rosso, Raffaella ^a   Bassetti, Dante ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antibiotics; Dalbavancin; Daptomycin; Glycylcycline; Gram positive; Linezolid; Oritavancin; Quinupristin dalfopristin; Remoplanin; Resistance

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; METICILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BLOOD; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; GRAM POSITIVE COCCI; HOSPITALIZATION; INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; URINARY TRACT INFECTION;

EID: 13444259924     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200407000-00004     Document Type: Review

References (60)

1. Cohn ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992, 257:1050-1055.
2. Wood MJ. Chemotherapy for Gram-positive nosocomial sepsis. J Chemother 1999, 11:10-16.
3. McGowan JE, Jr. The impact of changing pathogens of serious infections in hospitalized patients. Clin Infect Dis 2000, 31:S124-S130.
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002, 30:458-475.
5. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004, 48:275-280.
6. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002, 51(26):565-567.
7. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003, 36:429-439.
8. McGowan JE, Jr. Economic impact of antimicrobial resistance. Emerg Inf Dis 2001, 7:286-292.
9. Lamb HM, Figgilt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs 1999, 58:1061-1097.
10. Rybak MJ, Herscberger E, MoldovanT, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44:1062-1066.
11. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001, 32:S33-S145.
12. Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 2002, 8:791-800.
13. Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992, 30(Suppl A):67-75.
14. Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin- resistant Staphylococcus aureus with RP 5950. Antimicrob Agents Chemother 1995, 39:1419-1424.
15. Chow JW, Donahedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997, 24:90-91.
16. Werner G, Klare I, Witte W. Molecular analysis of streptogramin resistance in enterococci. Int J Med Microbiol 2002, 292:81-94.
17. Winston DJ, Emmanouilides C, Kroeber A, Hindler J, Bruckner DA, Territo MC, et al. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000, 30:790-797.
18. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, Dunn DL, Kreter B. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicenter of quinupristin-dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999, 44:263-273.
19. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000, 161:753-762.
20. Aventis. Quinupristin-dalfopristin (Synercid). Product Licence. Slough, Berks UK: Aventis; 2000.
21. Aventis. Synercid, quinupristin-dalfopristin. Package Insert. Collegeville, PA : Aventis; 1999.
22. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998, 42:3251-3255.
23. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001, 61: 525-551.
24. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40:839-845.
25. Bassetti M, Farrel PA, Callan DA, Topal JE, Dembry LM. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int J Antimicrob Agents 2003, 21:593-594.
26. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 21:358:207-208.
27. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000, 59:7-16.
28. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. J Am Med Dir Assoc 2004, 5:111-113.
29. Rubinstein E, Cammarat SK, Oliphant TH, Wunderink R, and the Linezolid Nosocomial Pneumonia study group. Linezolid (PNU 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double blind multicenter study. Clin Infect Dis 2001, 32:402-412.
30. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. for the Linezolid skin and soft tissue infections study group. Randomized comparison of linezolid (PNU 100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000, 44:3408-3413.
31. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant S. aureus infections. Clin Infect Dis 2002, 34: 1481-1490.
32. Lipsky BA, Itani K, Norden C, and the Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin Infect Dis 2004, 38:17-24.
33. Bassetti M, Di Biagio A, Cenderello C, Del Bono V, Palermo A, Cruciani M, et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect 2001, 43:148-149.
34. Kuter D, Tillotson CS. Hematological effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001, 21:1010-1013.
35. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis 2002, 35:348-349.
36. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003, 37:1389-1391.
37. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000, 46:523-526.
38. Barry AL, Fuchs PC, Braun SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American Medical Center The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. Antimicrob Agents Chemother 2001, 45:1919-1922.
39. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004, 53:669-674.
40. Silverman J, Oliver N, Ted A, Tongchuan L. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001, 45: 1799-1802.
41. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
42. Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003, 47: 3764-3767.
43. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; The Daptomycin 98-01 And 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
44. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000, 44:2948-2953.
45. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003, 47:1318-1323.
46. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-43.
47. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
48. Johnson AP. LY-333328 (oritavancin). Curr Opinion Anti-Infect Invest Drugs 1999, 1:87-95.
49. Coyle A, Ryback M. Activity of oritavancin, an investigational glycopeptide, compared to that of vancomycin against multidrug resistant S. pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemoter 2001, 45:706-709.
50. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P541].
51. Edlund C, Nord C. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000, 6:159.
52. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P937].
53. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother 2000, 44:2225-2229.
54. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of Gar-936 (tiglycycline), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002, 46:2535-2601.
55. Wong MT, Kauffman CA, Standiford HC, Linden P, Fort C, Fuchs HJ, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001, 33:1476-1482.
56. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P1031].
57. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P925].
58. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P926].
59. th European Congress of Clinical Microbiology and Infectious Diseases. Prague, May 2004 [abstract P931].
60. Bowker KE, Noel AR, MacGowan AP. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int J Antimicrob Agents 2003, 22:557-561.